• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    7/15/24 5:19:50 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIM alert in real time by email
    SC 13D/A 1 d782121dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    AIM IMMUNOTECH INC.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    00901B105

    (CUSIP Number)

    Todd Deutsch

    Ted D. Kellner

    c/o Baker & Hostetler LLP

    127 Public Square, Suite 2000

    Cleveland, Ohio 44114

    Attn: John J. Harrington

    (216) 621-0200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 15, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), §240.13d-1(f) or §240.13d-1(g), check the following box: ☐

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

    CUSIP No. 00901B105

     

     1.   

     Names of Reporting Persons

     

     Todd Deutsch

     2.  

     Check the Appropriate Box if a Member of a Group

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     PF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.   

     Sole Voting Power

     

     1,716,100

        8.  

     Shared Voting Power

     

     0

        9.  

     Sole Dispositive Power

     

     1,716,100

       10.  

     Shared Dispositive Power

     

     0

     11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,716,100

     12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☒

     13.  

     Percent of Class Represented by Amount in Row (11)

     

     3.0%(1)

     14.  

     Type of Reporting Person

     

     IN

     

    (1)

    Percentage ownership based on 57,136,680 shares outstanding as reported in a prospectus supplement filed pursuant to Rule 424 by the Company with the Securities and Exchange Commission on June 3, 2024.


    CUSIP No. 00901B105

     

     1.   

     Names of Reporting Persons

     

     Ted D. Kellner

     2.  

     Check the Appropriate Box if a Member of a Group

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     PF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.   

     Sole Voting Power

     

     394,000

        8.  

     Shared Voting Power

     

     1,099,000

        9.  

     Sole Dispositive Power

     

     394,000

       10.  

     Shared Dispositive Power

     

     1,099,000

     11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,493,000

     12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☒

     13.  

     Percent of Class Represented by Amount in Row (11)

     

     2.6%(1)

     14.  

     Type of Reporting Person

     

     IN

     

    (1)

    Percentage ownership based on 57,136,680 shares outstanding as reported in a prospectus supplement filed pursuant to Rule 424 by the Company with the Securities and Exchange Commission on June 3, 2024.


    SCHEDULE 13D

    This Amendment No. 4 (“Amendment No. 4”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on July 27, 2023 (the “Initial Schedule 13D” and together with Amendment No. 1 thereto filed on August 7, 2023, Amendment No. 2 thereto filed on August 28, 2023, Amendment No. 3 thereto filed on January 3, 2024 and this Amendment No. 4, the “Schedule 13D”) by Todd Deutsch and Ted D. Kellner (the “Reporting Persons”) with respect to the Common Stock, par value $0.001 per share, of AIM ImmunoTech Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment No. 4 shall have the meanings set forth in the Schedule 13D. This Amendment No. 4 amends Items 4 and 5 to the extent set forth below.

    Item 4. Purpose of the Transaction

    Item 4 is hereby supplemented as follows:

    In light of recent developments described below, the Reporting Persons are providing the following update on their plans with respect to the Company.

    Delaware Supreme Court Finds Breach of Duty of Loyalty by the Company’s Board

    On July 11, 2024, the Delaware Supreme Court ruled on Mr. Kellner’s previously disclosed appeal of the ruling of the Delaware Court of Chancery. The Delaware Supreme Court ruled in Mr. Kellner’s favor that all of the Company’s amended bylaws at issue in the appeal are inequitable and unenforceable. The Court found that the board’s motive was not to counter the threat of an uninformed vote. Rather, the board’s “primary purpose was to interfere with Kellner’s nomination notice, reject his nominees, and maintain control.” The Court ruled that the amended bylaws were the “product of an improper motive and purpose, which constitutes a breach of the duty of loyalty.” (emphasis added)

    The Delaware Supreme Court’s opinion can be found at https://courts.delaware.gov/Opinions/Download.aspx?id=366380.

    AIM and Counsel Sanctioned in Florida Action for Frivolous and Improper Litigation Conduct

    The findings of the Delaware Supreme Court regarding the board’s improper actions are part of a pattern. In April 2024, the Company and its counsel were sanctioned by the U.S. District Court, Middle District of Florida, for certain actions taken in the lawsuit that the Company initiated against the Reporting Persons and other defendants for an alleged violation of Section 13(d) of the Exchange Act. That action has been dismissed multiple times. The court found that the Company and its counsel committed sanctionable conduct by continuing to pursue arguments that were “factually and legally frivolous and advanced for an improper purpose” and that certain defendants in that action were entitled to fee reimbursement. The Reporting Persons continue to assert that the Company’s pursuit of these baseless claims against them and others in the U.S. District Court, Middle District of Florida, and now on appeal, is part of the board’s continuing effort to entrench itself and intimidate and harass stockholders who seek to bring accountability to the Company.


    Self-Interested Board Continues to Engage in Gross Corporate Waste and Disregard the Will of Stockholders

    These findings affirm the Reporting Persons’ belief that the Company’s board is not acting in the best interests of stockholders and change is desperately needed. The breach of the fiduciary duty of loyalty by Mr. Equals, Mr. Appelrouth and Dr. Mitchell, as has been conclusively determined by the Delaware Supreme Court ruling – and the subsequent actions of Ms. Bryan in joining their continuing scheme to entrench themselves and avoid accountability to stockholders – has been devastating to the Company and its stockholders. In furtherance of its breach of the fiduciary duty of loyalty and other self-interested efforts to entrench itself, the current board has engaged in gross waste and drained corporate resources, preventing any chance of success for the Company and the creation of value for stockholders. Based on the Company’s public disclosures, the Reporting Persons estimate the board has wasted over $15.0 million in attorneys’ fees and other expenses in pursuit of its improper motive and purpose of entrenchment over the past two years. And the board’s conclusive breach of its fiduciary duty of loyalty has thwarted the clearly expressed will of its stockholders, who in two successive elections have voted for change on the board and delivered proxies sufficient to elect the Reporting Persons at the 2024 Annual Meeting of Stockholders (despite the fact that the Company did not even include Mr. Kellner’s nominees on its proxy card).

    Board’s Wrongful Actions Devastating to Company’s Financial Condition and Prospects

    Having put the Company into a perilous financial position as a direct result of its wrongful actions, and eliminating the possibility of any institutional investor interest in the Company, the board now pursues vanishing, highly dilutive and increasingly desperate financing alternatives to the detriment of stockholders. In just the last few months, such transactions have included:

     

      •  

    receipt of a usurious two-year loan in the amount $2.5 million bearing an effective interest rate of approximately 25% per year (inclusive of OID and stated interest) from a lender controlled by an individual with a history of securities law violations – someone the SEC described as a “recidivist violator of the federal securities laws” in a 2020 complaint filed in U.S. District Court. See https://www.sec.gov/enforcement-litigation/litigation-releases/lr-24886.

     

      •  

    entry into an equity line agreement with a different entity controlled by this same troubling individual, providing that the Company may sell up to almost 10.0 million shares (almost 20% of outstanding shares at the time) to this entity at a discount to market price, and allowing this individual with a history of securities law violations to profit at the expense of existing stockholders when the shares are quickly dumped into the market.

     

      •  

    the sale of 5.6 million shares to a hedge fund for approximately $1.8 million of proceeds after expenses and granting that hedge fund warrants to purchase another 11.2 million shares at the same price – effectively granting the hedge fund the upside of approximately 25% of the Company for minimal proceeds. In just over a month since the initial sale, the investor has already sold over 30% (approximately 1.8 million shares) of the initial shares, confirming a lack of long-term interest and furthering downward pressure on the Company’s stock price.


    These transactions have done little to alleviate the Company’s financial distress, and only dig a deeper hole for the Company as shares are dumped on the market and long-term investors are ever more alienated and diluted by detrimental financings so the board can fund legal expenses to perpetuate their self-enrichment and keep themselves in office.

    Next Steps for the Reporting Persons

    As a result of all the foregoing, and the conclusive ruling that the board breached its duty of loyalty to the Company’s stockholders, the Reporting Persons reiterate that they continue to believe that for the Company to have any chance of success, significant change in the board is urgently needed.

    Despite the ruling of the Delaware Supreme Court that the board breached its fiduciary duty of loyalty, the Court’s ruling did not grant the relief sought by Mr. Kellner.

    The Reporting Persons are continuing to review the ruling and the alternatives that may be available to them, whether through litigation proceedings, additional actions that may be taken in their capacities as significant stockholders of the Company, or otherwise. Without limiting the foregoing, the Reporting Persons are reviewing the legal options, actions and remedies that may be available to them and that they may choose to pursue. The Reporting Persons are also considering whether to nominate directors for the Company’s 2025 Annual Meeting of Stockholders. The Reporting Persons expect the board to promptly amend the Company’s invalid and unenforceable bylaws in a way that is consistent with its fiduciary duties.

    The Reporting Persons reiterate that it is not their intention, either alone or acting together with any other persons or group of persons, to acquire a control stake in the shares of Common Stock. Beyond the foregoing, the Reporting Persons will review their investments in the Company on a continuing basis and may in the future determine (1) to acquire additional securities of the Company, through open market purchases, private agreements or otherwise, (2) to dispose of all or a portion of the securities of the Company owned by them or (3) to take any other available course of action. Notwithstanding anything contained herein, the Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. In reaching any decision as to its course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that they would take into consideration a variety of factors, including, but not limited to, the following: the actions of the Company’s board; the Company’s business and prospects; other developments concerning the Company and its businesses generally; other business opportunities available to Company and the Reporting Persons; developments with respect to the businesses of the Reporting Persons; changes in law and government regulations; general economic conditions; and money and stock market conditions, including the market price of the securities of the Company.

    Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Company, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D.


    Item 5. Interest in Securities of the Issuer

    Item 5 is hereby supplemented as follows:

     

      (a)

    As of the date of this Amendment No. 4, Mr. Kellner is the beneficial owner of 1,493,000 shares of Common Stock, or 2.6% of the Company’s outstanding shares, and Mr. Deutsch is the beneficial owner of 1,716,100 shares of Common Stock, or 3.0% of the Company’s outstanding shares The Group consisting of Mr. Deutsch and Mr. Kellner owns an aggregate of 3,209,100 shares of Common Stock, or 5.6% of the Company’s outstanding shares. The ownership percentages above are based on 57,136,680 shares of Common Stock outstanding as reported as reported in a prospectus supplement filed pursuant to Rule 424 by the Company with the Securities and Exchange Commission on June 3, 2024.


    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

    Date: July 15, 2024

     

    By:   /s/ Todd Deutsch
      TODD DEUTSCH
    By:   /s/ Ted D. Kellner
      TED D. KELLNER
    Get the next $AIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

      OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) (OTC:AIMI) ("AIM" or the "Company") today announced the presentation of clinical trial data involving AIM's drug Ampligen by Pawel Kalinski, MD, PhD, at the recent Annual Meeting of the American Association of Immunologists held May 3-7, 2025, in Honolulu, HI. The paper, titled "Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of the TME," discussed the unique two-level selectivity of action of Ampligen when used as a part of chemokine modulation and combined with PD-1 blockade or chemotherapy. Dr. Kalinski d

      5/8/25 8:45:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

      OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC:AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on. For additional information, refer to AIM's Definitive Proxy Statement filed April 2, 2025. About AIM ImmunoTech Inc.AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multipl

      4/7/25 1:26:48 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

      OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the "NYSE American" or the "Exchange") that it had suspended trading of the Company's common stock and of its determination to commence delisting proceedings of the Company's common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company

      4/4/25 4:45:00 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group resumed coverage on AIM ImmunoTech with a new price target

      Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00

      2/9/21 4:10:39 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    SEC Filings

    See more

    $AIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AIM ImmunoTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

      4/4/25 5:56:40 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

      4/4/25 10:30:09 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by AIM ImmunoTech Inc.

      DEF 14A - AIM ImmunoTech Inc. (0000946644) (Filer)

      4/2/25 4:45:33 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:16 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:19 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:17 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:16 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:19 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:17 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

      SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

      12/17/24 4:11:23 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by AIM ImmunoTech Inc.

      SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

      11/14/24 3:21:36 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

      SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

      9/11/24 5:40:58 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    Financials

    Live finance-specific insights

    See more
    • AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business

      3/27/25 8:05:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      – Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu

      11/15/24 7:29:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

      OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Invest

      11/6/24 9:00:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    Leadership Updates

    Live Leadership Updates

    See more
    • AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

      OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

      2/26/25 8:30:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

      Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo

      12/12/24 3:00:00 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kellner Group Announces Support from Another Former AIM Senior Executive

      Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t

      12/12/24 8:16:14 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care